CO2023000016A2 - Proteínas enpp1 o enpp3 solubles y sus usos - Google Patents

Proteínas enpp1 o enpp3 solubles y sus usos

Info

Publication number
CO2023000016A2
CO2023000016A2 CONC2023/0000016A CO2023000016A CO2023000016A2 CO 2023000016 A2 CO2023000016 A2 CO 2023000016A2 CO 2023000016 A CO2023000016 A CO 2023000016A CO 2023000016 A2 CO2023000016 A2 CO 2023000016A2
Authority
CO
Colombia
Prior art keywords
enpp3
enpp1
proteins
deficiency
compositions
Prior art date
Application number
CONC2023/0000016A
Other languages
English (en)
Inventor
Zhiliang Cheng
Demetrios Braddock
Paul Stabach
Steven Jungles
Original Assignee
Inozyme Pharma Inc
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inozyme Pharma Inc, Univ Yale filed Critical Inozyme Pharma Inc
Publication of CO2023000016A2 publication Critical patent/CO2023000016A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)

Abstract

En determinados aspectos, la presente invención proporciona polipéptidos ENPP1 o ENPP3 solubles novedosos, así como composiciones y métodos para usar esas variantes para tratar una indicación 5 asociada a una deficiencia de ENPP1 o ENPP3. Las composiciones y métodos proporcionados en la presente descripción son útiles para tratar enfermedades asociadas con una deficiencia de ENPP1 o ENPP3 tales como calcificación patológica u osificación patológica.
CONC2023/0000016A 2020-06-09 2023-01-03 Proteínas enpp1 o enpp3 solubles y sus usos CO2023000016A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063036833P 2020-06-09 2020-06-09
PCT/US2021/036494 WO2021252549A1 (en) 2020-06-09 2021-06-08 Soluble enpp1 or enpp3 proteins and uses thereof

Publications (1)

Publication Number Publication Date
CO2023000016A2 true CO2023000016A2 (es) 2023-02-16

Family

ID=76731053

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0000016A CO2023000016A2 (es) 2020-06-09 2023-01-03 Proteínas enpp1 o enpp3 solubles y sus usos

Country Status (14)

Country Link
US (1) US20230313158A1 (es)
EP (1) EP4162036A1 (es)
JP (1) JP2023529892A (es)
KR (1) KR20230042263A (es)
CN (1) CN116157145A (es)
AR (1) AR122578A1 (es)
AU (1) AU2021286502A1 (es)
BR (1) BR112022024958A2 (es)
CA (1) CA3181983A1 (es)
CO (1) CO2023000016A2 (es)
IL (1) IL298853A (es)
MX (1) MX2022015772A (es)
TW (1) TW202214849A (es)
WO (1) WO2021252549A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342103A (zh) * 2022-03-30 2023-11-01 耶魯大學 用於治療、改善及／或預防特發性瀰漫性骨質增生症(dish)的方法及組成物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
JPH07507059A (ja) 1992-03-25 1995-08-03 デポムド　システムズ，インコーポレイテッド アルキル置換セルロースをベースとする持続放出性経口薬剤投与剤形
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
EP1242057A2 (en) 1999-11-02 2002-09-25 DepoMed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
JP2003521507A (ja) 2000-02-04 2003-07-15 ディポメド，インコーポレイティド ゼロ次薬物放出に接近するシェル−コア剤形
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US7413751B2 (en) 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
MX2009005572A (es) 2006-11-28 2009-07-30 Proyecto Biomedicina Cima Sl Vector viral y sus aplicaciones.
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
WO2012125182A1 (en) 2011-03-11 2012-09-20 Synageva Biopharma Corp Npp1 fusion proteins
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
EP3194430A1 (en) 2014-09-16 2017-07-26 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
MX2017007946A (es) * 2014-12-19 2017-09-15 Alexion Pharma Inc Metodos para tratar la calcificacion de tejidos.
RU2757417C2 (ru) 2015-05-19 2021-10-15 Йейл Юниверсити Композиции для лечения патологических состояний кальцификации и способы их применения
EP3471747A1 (en) * 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
CA3096821A1 (en) * 2017-09-27 2019-04-04 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
AU2019267545A1 (en) * 2018-05-08 2020-11-26 Yale University Compositions and methods for reducing progression of nephrolithiasis
WO2020047520A1 (en) 2018-08-31 2020-03-05 Yale University Enpp1 polypeptides and methods of using same
MX2021012197A (es) 2019-04-05 2022-01-06 Univ Yale Polipeptidos de ectonucleotido pirofosfatasa (enpp1) y metodos de uso de los mismos.

Also Published As

Publication number Publication date
IL298853A (en) 2023-02-01
TW202214849A (zh) 2022-04-16
JP2023529892A (ja) 2023-07-12
AU2021286502A1 (en) 2023-01-19
CN116157145A (zh) 2023-05-23
AR122578A1 (es) 2022-09-21
MX2022015772A (es) 2023-05-19
US20230313158A1 (en) 2023-10-05
WO2021252549A1 (en) 2021-12-16
KR20230042263A (ko) 2023-03-28
CA3181983A1 (en) 2021-12-16
BR112022024958A2 (pt) 2022-12-27
EP4162036A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
CR20210387A (es) Inhibidores de kif18a
MX2021007104A (es) Inhibidores de kif18a.
BR112023016299A2 (pt) Composições e métodos para inibir kras
MX2022001302A (es) Inhibidores de kif18a.
EA202090817A1 (ru) Триспецифические белки и способы их применения
MX2022001181A (es) Inhibidores de kif18a.
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
ECSP077280A (es) Moduladores de quinasa de pirrolo-piridina
EA201490697A1 (ru) Белки с двойной функцией для лечения метаболических расстройств
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
MX2020004712A (es) Vesiculas extracelulares modificadas geneticamente con proteinas.
CO2022003552A2 (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
ATE466081T1 (de) Zusammensetzungen und verfahren zur regulierung eines komplementsystems
CO2023000016A2 (es) Proteínas enpp1 o enpp3 solubles y sus usos
PE20160519A1 (es) Compuestos de tetrahidrocarbozol y carbozol carboxamida sustituidos utiles como inhibidores de cinasa
CL2021001490A1 (es) Constructos de iarn modificados químicamente y usos de estos
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
CL2021001209A1 (es) Constructos de suministro para transcitosis y métodos relacionados
AR101735A1 (es) Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro)
EA202092459A1 (ru) Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
CL2021001488A1 (es) Transposasa de piggybac mutada
BR112022009279A2 (pt) Tratamento de angioedema hereditário com vetores de terapia gênica específicos do fígado
UY39699A (es) Anticuerpos anti-tau y usos de estos
BR112022012473A2 (pt) Composição de tratamento capilar, e, métodos para tratar cabelo, para melhorar a condição do cabelo e para diminuir o ph do cabelo